Open
The Marked Chart Wire · Health
AstraZeneca ADCs
AstraZeneca will seek approval for sonesitatug vedotin after a trial showed a 42 percent reduction in death risk for gastric cancer patients. The company projects peak annual sales of $3 billion to $5 billion for the drug.
Prices from Live · updated 11:30 AM ET. Each tile opens the stock's chart and news.
New to this? Read: Reading a stock chart
Lung Cancer
Amgen reported that adding its medication to AstraZeneca’s immunotherapy reduced the chance of death by 58 percent for individuals with advanced lung tumors.
Novartis
Novartis said its drug remibrutinib met primary endpoints in phase 3 trials for rhabdomyosarcoma. The treatment cut relapse rates by 35 percent compared with a rival therapy, and the company plans to seek global approval.
Eikon Therapeutics
Eikon Therapeutics stated that EIK1001, used with standard treatments, showed lasting results in advanced non-small cell lung cancer. The company said the side effect profile allows for outpatient care.
Lung Cancer
Hutchmed announced that its Safron Phase III study showed a 45 percent reduction in disease progression or death risk for patients with specific lung cancer mutations when using Orpathys with Tagrisso instead of chemotherapy.
BeOne Medicines
BeOne Medicines presented ESMO data for its experimental bispecific antibody. The drug showed a 36 percent confirmed response rate in advanced liver cancer cases with a good safety profile at the Phase 3 dose.
Agenus
Agenus disclosed Sunday that 72 percent of patients with locally advanced dMMR colon cancer showed no residual disease at surgery after six weeks of treatment. The trial also met its primary endpoint, with 83 percent achieving a major pathologic response.
Fast headlines, summarized. Not verified and not advice. Check the full story before you act.